A Keytruda combo trial of the company’s Tavo shows an improving dataset, as remissions appear to deepen with time.
Among late-breaking abstracts whose titles have just gone live two mechanisms have a chance to redeem themselves.
The company’s deal with Dragonfly shows that disappointments have not eliminated interest in cytokine approaches.
The company struggles to move the needle at the SITC meeting with an up-to-date cut of its first-line melanoma trial of NKTR-214 and Opdivo.
Novartis's $4m price target for AVXS-101 fuels concerns that too many new gene therapies could overburden payers without a hard look at how they are financed.